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Resveratrol—a natural polyphenolic compound—was ﬁrst discovered in the 1940s. Although initially used
for cancer therapy, it has shown beneﬁcial effects against most cardiovascular and cerebrovascular dis-
eases. A large part of these effects are related to its antioxidant properties. Here we review: (a) the
sources, the metabolism, and the bioavailability of resveratrol; (b) the ability of resveratrol to modulate
redox signalling and to interact with multiple molecular targets of diverse intracellular pathways; (c) its
protective effects against oxidative damage in cardio-cerebro-vascular districts and metabolic disorders
such as diabetes; and (d) the evidence for its efﬁcacy and toxicity in humans. The overall aim of this
review is to discuss the frontiers in the ﬁeld of resveratrol’s mechanisms, bioactivity, biology, and health-
related use.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
1.1. Structure and history of resveratrol
Resveratrol—3,40,5-trihydroxy-trans-stilbene (MW: 228.2)—is a
natural non-ﬂavonoid polyphenol compound containing a stilbene
structure similar to that of estrogen diethylstilbestrol (Fig. 1a). It is
a fat-soluble compound existing in cis, trans-, and piceid isomeric
forms (Fig. 1b). It was ﬁrst isolated in 1940 from the roots of white
hellebore (Veratum grandiﬂorum O. Loes) and later, in 1963, from
the roots of Polygonum cupsidatum, a plant used in traditional Chi-
nese and Japanese medicine (Nonomura et al., 1963). Resveratrol
has been in use since ancient times as an Indian herbal preparation
termed ‘Darakchasava’, which is derived from fermented grapes.
Remarkably, the effects described for Darakchasava more than
4500 years ago (Singh et al., 2013) are the same described for
resveratrol today. Today, Darakchasava is produced by several
pharmaceutical companies and contains about 1.3–6.0 mg/L resve-
ratrol (Paul et al., 1999). Despite its ancient discovery, the ﬁrst real
interest in resveratrol came in 1992 when it was postulated toexplain some of the cardio-protective effects of red wine (Siemann
and Creasy, 1992). It was suggested to be the solution to the
‘‘French Paradox’’, a term used to describe the observation that
the French population had a very low incidence of cardiovascular
disease despite a high consumption of wine and saturated fat
(Liu et al., 2007). In 1997, Jang and colleagues reported that resve-
ratrol acts as a chemo-preventive agent, due to its ability to inhibit
carcinogenesis at multiple stages (Jang et al., 1997). More recently,
anti-inﬂammatory and antioxidant properties have been reported
also (Baur and Sinclair, 2006; Vang et al., 2011), so today it has be-
come a highly important natural active ingredient with potential
therapeutic effects and market prospects.
1.2. Sources of resveratrol
Resveratrol is produced by various plants as a defense against
stress, injury, excessive sunlight, ultraviolet radiation, infection,
and invading fungi (Singh et al., 2013). For example, the roots of
the plant P. cuspidatum, much cultivated in Asia, provides a rich
source of resveratrol from which commercially available trans-res-
veratrol (98% pure) is isolated by high-speed counter-current chro-
matography (Yang et al., 2001). Resveratrol is also considered a
nutraceutical present in grapes, peanuts, pine trees, cassia and
other plants, and many food products (Ramprasath et al., 2010;
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red wines contain between 0.2 and 5.8 mg/L, depending upon the
grape variety, whereas white wines contain 0.68 mg/L (Romero-
Pérez et al., 1999; Sato et al., 1997). This variation derives from
the fact that red wine is extracted with the grape skin intact,
whereas white wine is fermented after removal of the skin. Red
wine contains more trans-resveratrol than white wine, whereas
white has a higher concentration of cis-resveratrol (Feijóo et al.,
2008). Concentrations of resveratrol in some natural foods are
given in Table 1.
1.3. Metabolism of resveratrol
In rats and humans, resveratrol is a molecule involved in the
enterohepatic cycle of metabolism. In particular, after resveratrol
is taken up rapidly by enterocytes, it is metabolized to glucuro-
nide- (3-O-glucuronide and 40-O-glucuronide) and sulfate-conju-
gates (3-O-sulfate), which are secreted back into the intestine
where they may be deconjugated and reabsorbed or excreted in
the feces (Walle et al., 2004; Marier et al., 2002). The enterohepatic
cycle thus reduces the concentration of the free compound reach-
ing target tissues. So, the low concentration of resveratrol found in
blood is likely explained by this enterohepatic cycle and its rapid
metabolism in the liver. Apart from dihydroresveratrol, the major
metabolites formed are the glucuronide- and sulfate-conjugates,
including disulfates and mixed sulfate-glucuronides (Wang et al.,
2005). Concentrations of these metabolites are reported to be high-
er than resveratrol post-absorption and to have longer half-lives
(Andres-Lacueva et al., 2009; Polycarpou et al., 2013). In fact, the
majority of orally dosed resveratrol is found in urine as sulfate-
or glucuronic acid-conjugates (Singh et al., 2013). In particular,
the proportion of glucuronide- and sulfate-metabolites are re-
ported to change depending on the tissue and species considered
(Juan et al., 2010; Azorín-Ortuño et al., 2011): glucuronideFig. 1. (a) Structure of resveratrol. (b) Structures of trans and cis isomers of
resveratrol and piceid.
Table 1
Resveratrol content in certain natural foods (Prasad, 2012).
Food stuff Concentration range
Grapes 0.16–3.54 lg/g
Dry grape skin 24.06 lg/g
Red grape juice 0.5 mg/L
White grape juice 0.05 mg/L
Red wine 0.1–14.5 mg/L
White wine 0.1–2.1 mg/L
Peanuts 0.02–1.92 lg/g
Pistachios 0.09–1.67 lg/gconjugates are reported to be the main metabolites in rodents,
whereas primarily sulfates are found in humans (Walle, 2011);
moreover, the quantity of glucuronides is higher than sulfates in
rat testes and liver, but not in lung (Juan et al., 2010). As a result,
many authors are beginning to investigate the effects of resveratrol
metabolites on in vitro and in vivomodels: for example, resveratrol
3-O-D-sulfate, as well as resveratrol 3-O-D-glucuronide and resve-
ratrol 4-O-D-glucuronide, was found to inhibit cycloxygenase
(COX1 and COX2) (Calamini et al., 2010), whereas 3-O-D-sulfate
and resveratrol 4-O-D-glucuronide were reported to reduce triacyl-
glycerol content in 3T3-L1 adipocytes (Lasa et al., 2012). Recently,
Polycarpou et al. demonstrated that resveratrol glucoronides are
able to arrest the growth of different human colon cancer cells
(Polycarpou et al., 2013). Thus, many of the effects reported for
resveratrol may be due to the action of resveratrol’s metabolites.
1.4. Bioavailability of resveratrol and plasma levels
Many studies have shown that resveratrol, like other polyphe-
nols, has very low bioavailability (Goldberg et al., 2003). The bio-
availability and pharmacokinetics of resveratrol have been
studied in humans and in animal models. In humans, resveratrol
is rapidly taken up after oral consumption of a low dose, with
the plasma resveratrol concentration peaking about 30 min after
consumption (Goldberg et al., 2003); in rats, the plasma half-life
of resveratrol was reported to be 12–15 min after oral administra-
tion (Gescher and Steward, 2003). A study performed by Walle
et al. using 14C-trans-resveratrol (25 mg orally) in humans showed
that 70% of the resveratrol dose was absorbed by the body (Walle
et al., 2004); a similar ﬁnding (50%) was reported for rats (Marier
et al., 2002). The glucuronide- and sulfate-conjugated metabolites
of resveratrol peaked in plasma at 30–60 min post-administration,
with a plasma half-life of 9.2 h. (Walle et al., 2004). In contrast,
only small amounts of unmodiﬁed resveratrol (<5 ng/mL) were
detected in plasma in a similar timeframe (Singh et al., 2013). In
another study conducted on mice, rats, and humans, it was shown
that within 24 h after administration of 0.03 mg/kg body weight
(BW) resveratrol, nearly 50% of the resveratrol was excreted in
the urine. However, because <25% of the resveratrol was found in
the urine with a dose of 1 mg/kg BW, these results suggest that res-
veratrol undergoes rapid gastrointestinal absorption in all the
three species studied (Meng et al., 2004).
The amount of resveratrol ingested from dietary sources, such
as red wine and juices, rarely exceeds 5 mg/L and often results in
plasma levels that are either not detectable or several orders of
magnitude below the micromolar concentrations that are
employed in experimentation in vitro, i.e., 32 nM to 100 lM
(Smoliga et al., 2011). For example, administration of about
25 mg resveratrol resulted in plasma concentrations of the free
form that ranged from 1 to 5 ng/mL (Almeida et al., 2009), and
administration of higher doses (up to 5 g) increased the plasma
resveratrol concentration to about 500 ng/mL (Boocock et al.,
2007). The low doses of resveratrol observed in the plasma after
ingestion are very low, as the concentrations used in vitro are not
reached. However, due to its lipophilic character, tissue levels of
resveratrol may be higher than those found in plasma (Timmers
et al., 2012). Nonetheless, some of the biological effects of resvera-
trol are observed at very low concentrations (Waite et al., 2005;
Pearce et al., 2008), bringing forward the idea that resveratrol
exerts its major effects on intestinal tissue, affecting the rest of
the body through secondary effects that are independent of the
plasma levels reached by the compound (Baur et al., 2006). In
rodent models, the doses employed normally range from as low
as 0.1 mg/kg BW to up to 1000 mg/kg BW, with even higher or low-
er doses occasionally being used (Baur et al., 2006). Interestingly,
studies show that the bioavailability of resveratrol can be
Table 2
Antioxidant activity of resveratrol. The antioxidant molecules and enzymes stimulated by resveratrol are given on the left of the table; enzymes down-regulated by resveratrol are
given on the right.
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(Howells et al., 2011), by enhancing delivery methods, such as lipo-
somal encapsulation (Narayanan et al., 2009), or by combining it
with piperine, a natural product from black pepper (Piper spp.)
(Johnson et al., 2011).
1.5. Aims of the review
Studies performed in vivo and in vitro have shown that resvera-
trol exerts pleiotropic effects and can prevent or slow the progres-
sion of several pathological conditions, including cardiovascular
and metabolic diseases, ischemic brain injuries, and cancer (Jang
et al., 1997; Inoue et al., 2003), as well as extend lifespan in differ-
ent organisms and enhance stress resistance (Yang et al., 2013).
The aim of the present review is to highlight the antioxidant effects
of resveratrol, focusing our attention on cardiovascular, cerebral,
and metabolic disorders, such as diabetes, and reporting also the
results of the main clinical trials.
2. Antioxidant properties of resveratrol
A well-documented method for reducing oxidative stress is to
reduce caloric intake by selecting appropriate foods (Nisoli et al.,
2005). It is well known that nutrients, whether water soluble or
lipid soluble, comprise an important aspect of the antioxidant de-
fense system. Beyond their normal occurrence in cells and tissues
of living organisms, free radicals and reactive species are present
in the unhealthy foods that people consume every day, inducing
undesirable reactions like oxidation of lipids, proteins, nucleic
acids, and carbohydrates. An impaired ability to scavenge free rad-
icals and reactive species, as a consequence of decreased levels of
antioxidant cellular defense systems or excessive free-radical pro-
duction, is common in cerebral and cardiovascular diseases in hu-
mans and animals (Alissa and Ferns, 2012).
Resveratrol plays a prominent role among the foods exerting an
antioxidant activity. The main antioxidant activities of resveratrol
are summarized in Table 2 (Rocha et al., 2009; Li et al., 2006; Juan
et al., 2005; Kohnen et al., 2007). The data suggest that resveratrol
exerts its action in different ways: it scavenges reactive oxygen
species (ROS), increasing the activity of enzymes that metabolize
ROS, such as superoxide dismutase (SOD), or decreases the activity
of enzymes that play a role in ROS production.
2.1. Impact of resveratrol on cardiovascular diseases
2.1.1. Effects of resveratrol on lipid peroxidation
Oxidative stress is one of the risks of cardiovascular disease
(CVD), such as atherosclerosis, and is characterized by theproduction of free radicals that lead to the oxidation of low density
lipoprotein (LDL) (Kovanen and Pentikaïnen, 2003; Puca et al.,
2013). It is well known that oxidized LDL accumulates at the site
of atherosclerotic lesions (Ramprasath and Jones, 2010), contribut-
ing to the formation of macrophage foam cells that induce endothe-
lial dysfunction (Mietus-Snyder et al., 2000), a common marker of
CVD. Because it prevents lipid peroxidation, inhibits uptake of oxi-
dized LDL, and inhibits lipoxygenase activity (Maccarrone et al.,
1999; Kovanen and Pentikaïnen, 2003), resveratrol is a good
candidate for the ﬁght against oxidative stress in atherosclerosis
(Fremont et al., 1999; Leighton et al., 1999; Bhavnani et al., 2001;
Olas andWachowicz, 2002). Oxidation of LDL cholesterol is strongly
associated with risk of CVD (Holvoet, 2004). In this regard, resvera-
trol was found in rat liver microsomes to inhibit iron-induced, as
well as ultraviolet-irradiated, lipid peroxidation and to prevent
LDL oxidation by copper (Fauconneau et al., 1997; Miura et al.,
2000); moreover, Rocha et al. found a reduction in oxidized LDL
in rats fed on a high fat diet when treated with resveratrol for
45 days at a dose of 1 mg/kg BW/day (Rocha et al., 2009).
Resveratrol also prevents the oxidation of polyunsaturated
fatty acids found in LDL (Miller and Rice-Evans, 1995), inhibits
the oxidized LDL uptake in the vascular wall in a dose-dependent
manner (Fremont, 2000), and prevents damage caused to lipids by
peroxidation (Frankel and Waterhouse, 1993; Leighton et al.,
1999). Its effect was found to be stronger than the well-known
antioxidant a-tocopherol (Frankel and Waterhouse, 1993). The
protective effect of resveratrol against lipid peroxidation was also
found in the heart of rats exposed to low doses of doxorubicin, an
antitumor drug that causes oxidative stress (Dudka et al., 2012),
and in the post-ischemic, re-perfused myocardium of rats (Ray
et al., 1999).
2.1.2. Effects of resveratrol on antioxidant mechanisms protecting
against oxidative cardiovascular pathophysiology
It has been recently demonstrated that resveratrol reduces
endothelial dysfunction in vessel from dyslipidemic patients with
hypertension; this antioxidant action of resveratrol was mediated
by upregulation of manganese superoxide dismutase (Mn-SOD)
via a mechanism dependent upon nuclear factor (erythroid-derived
2)-like 2 (NRF2) (Carrizzo et al., 2013). This ﬁnding in humans was
in agreement with experimental models showing that resveratrol
was able to increase Mn-SOD expression in the mouse myoblast
line C2C12 via nuclear translocation and activation of sirtuin 1
(SIRT1), a NAD+-dependent class III histone deacetylase. In obese
rats, Franco et al. found that the activity of both SOD and catalase
(CAT) was increased in plasma by the administration of resveratrol,
preventing oxidative stress and reducing the risk of hypertension
(Franco et al., 2013). Similarly, hepatic expression of SIRT1 and
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after 4 weeks of treatment (Nakata et al., 2012). The stimulation
of Mn-SOD levels was also reported in cultured cardiomyocytes
and in coronary artery endothelial cells (Movahed et al., 2012; Ung-
vari et al., 2009; Tanno et al., 2010). In human aortic smoothmuscle
cells, it increased the expression of heme oxygenase-1 (HO-1),
which degrades pro-oxidant heme to biliverdin/bilirubin, iron,
and carbon monoxide, consequently reducing ROS levels (Juan
et al., 2005). In vascular smooth muscle cell, resveratrol reduced
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
activity induced by angiotensin II, and enhanced SOD activity, pro-
moting a signiﬁcant decrease in ROS generation (Zhang et al., 2013).
Moreover, resveratrol inhibits the expression of NADPH oxidase in
cardiovascular tissues and reduces O2 production from mitochon-
dria (Li et al., 2013). Recently, it has been demonstrated that resve-
ratrol-mediated upregulation of GCH-1 (GTP cyclohydrolase I) and
BH4 (tetrahydrobiopterin) biosynthesis prevents endothelial nitric
oxide synthase (eNOS) uncoupling and reduces ROS production in
the vasculature (Carrizzo et al., 2013).
Xanthine oxidase has been shown to be an important source of
oxidant production in vascular endothelium (Sabán et al., 2013)
and also a contributing factor to oxidative stress during strenuous
exercise. On this issue, has been demonstrated that resveratrol
inhibits hypoxanthine/xanthine oxidase in mice, reducing ROS
generation (Ryan et al., 2010). Moreover, it has been reported that
resveratrol treatment decreases ROS levels in high-capacity run-
ner rats especially in endurance racing: in particular, it increased
the aerobic performance and upper-limb strength of these rats.
This beneﬁcial effect is mediated by enhanced mitochondrial bio-
genesis, with activation of the AMPK–SIRT1–PGC-1a pathway
(Hart et al., 2013). Also, resveratrol inhibited oxidative stress
in vivo by scavenging ROS and attenuating peroxyl radicals,
hydrogen peroxide (H2O2), and superoxide radical (*O2) (Liu
et al., 2003; Chen et al., 2004). In rat pheochromocytoma (PC12)
cells, which are characterized by a high level of catecholamines,
1–100 mmol/L resveratrol inhibited production of ROS (Jang and
Surh, 2001).
Resveratrol has also been shown to inhibit *O2 and H2O2 pro-
duced in murine macrophages stimulated by lipopolysaccharides
(LPS) or phorbol esters (Martinez and Moreno, 2000). In embryonic
rat cardiac cells, it prevented mitochondrial damage induced by
H2O2 (He et al., 2012). Moreover, resveratrol activates an important
survival signal pathway consisting in A1 and A3 adenosine recep-
tor-mediated activation of the PI3K–AKT pathway and the cAMP
response element-binding protein (CREB), promoting upregulation
of Bcl-2 and, hence, protecting cardiac tissue from cell death (Li
et al., 2012).
In human platelets, resveratrol signiﬁcantly lowers the levels
of thiol proteins (Olas et al., 2004). It also hampers platelet
aggregation and activation: phytoalexin seems to inhibit the
interaction of platelets with collagen and thrombin in vitro in iso-
lated platelets and in animal models. The mechanism remain un-
clear, but it seems that inhibition of prostaglandin H synthase 1
and cyclooxygenase-1 over COX2 represent possible mechanisms
for the anti-platelet aggregation effect of resveratrol (Borriello
et al., 2010).
In a wide variety of cells, such as myeloid, lymphoid, and epi-
thelial cells, resveratrol has been shown to prevent the production
of ROS induced by tumor necrosis factor (TNFa) (Manna et al.,
2000). In aortic endothelial cells, resveratrol (100 nM) was found
to prevent TNFa-induced oxidative stress through a reduction in
NADPH oxidase activity and the production of H2O2 and *O2
(Vecchione et al., 2009a,b). Recently, Wang et al. demonstrated
that resveratrol decreases apoptosis induced by oxidative stress
in vascular adventitial ﬁbroblasts of rats treated with TNF-a, acting
by activating SIRT1 (Wang et al., 2013).Other mechanisms through which resveratrol has been sug-
gested to exert CVD-preventing antioxidant effects are:
(a) competition with coenzyme Q, decreasing oxidative chain
complex III, and increasing endogenous antioxidants and
phase 2 enzymes in rat cardiomyocytes (Cao and Li, 2004);
(b) antioxidant effects against linoleic acid peroxidation in
sodium dodecyl sulfate and cetyltrimethylammonium bro-
mide micelles (Fang et al., 2002; Fang and Zhou, 2008);
(c) maintenance of glutathione levels in oxidatively stressed
human peripheral blood mononuclear cells, and elevation
of glutathione levels in human lymphocytes activated by
H2O2 (Losa, 2003; Olas et al., 2004). A strong dose-depen-
dent induction of antioxidant genes was demonstrated
when rats were supplemented with 0.3, 1, and 3 g/kg BW/
day resveratrol for 28 days (Hebbar et al., 2005);
(d) interaction with AMP-activated protein kinase (AMPK) in
diabetic LDL-receptor-deﬁcient mice (Zang et al., 2006),
and PPARc coactivator (PGC)-1a in mouse cardiac tissue
(Lagouge et al., 2006);
(e) reduction in the rate of cytochrome C oxidation by hydroxyl
radicals (Turrens et al., 1997). Jiian et al. reported that resve-
ratrol signiﬁcantly reduced cytochrome C protein levels in
the heart tissue of rats subjected to trauma-hemorrhage;
the authors suggest that resveratrol may be important for
mitochondrial membrane integrity, leading to a reduction
of ROS generation (Jian et al., 2012)
2.1.3. Effects of resveratrol on nitric oxide metabolism
Nitric oxide (NO) plays a critical role in maintaining cardiovas-
cular homeostasis (Dudzinski et al., 2006; Dudzinski and Michel,
2007; Puca et al., 2012). In the vasculature, NO is constitutively
synthesized by eNOS and acts by relaxing vascular smooth muscle
cells and upregulating blood ﬂow, and so prevents thrombogenic
and atherogenic processes. It has been demonstrated both
in vitro and in vivo that resveratrol is involved in NO metabolism.
For example, 30 lM resveratrol inhibited the contractile response
to phenylephrine in isolated rat aorta (Chen and Pace-Asciak,
1996). Similarly, 70 lM resveratrol caused relaxation of isolated
human saphenous vein and internal mammary artery rings (Rakici
et al., 2005), and relaxed porcine arterial rings pre-contracted with
KCl (Li et al., 2006). In those studies, the inhibitory effect of resve-
ratrol was reversed by removal of the endothelium or by inhibition
of eNOS. Orallo et al. reported that resveratrol (1–30 lM) relaxed
the contractile response of rat aortic rings to phenylephrine and
KCl in an NO-dependent manner (Orallo et al., 2002); however, it
was suggested that resveratrol does not affect eNOS activity, but
instead inhibits NADH/NADPH oxidase, with a decreased reduction
in superoxide generation, leading to improved NO bioavailability.
Resveratrol rapidly increased NO production in cultured endothe-
lial EA.hy926 cells, although at a high concentration (10 lM)
(Wallerath et al., 2002). In bovine aortic endothelial cells, 100
nM resveratrol for 15 min was found to increase NO production
through phosphorylation of AKT, extracellular signal-regulated ki-
nase (ERK)1/2, and eNOS (Wang et al., 2011). Klinge et al. proposed
that resveratrol increases NO production throughmembrane estro-
gen receptors (ERs) in bovine aortic cells, human umbilical vein
cells, and human microvascular endothelial cells (Klinge et al.,
2005, 2008) by rapid activation of Src and ERK1/2, leading to eNOS
activation. However, as demonstrated by studies on isolated por-
cine coronary arteries (Li et al., 2006) and murine endothelial f-2
cells (Takahashi et al., 2009), ER antagonists do not inhibit resvera-
trol-stimulated NO production.
Wallerath et al. reported that the treatment of cultured endo-
thelial cells with resveratrol (10–100 lm) for 24–72 h upregulated
eNOS mRNA and protein expression levels, resulting in increased
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larly, other studies conﬁrmed that high concentrations of resvera-
trol signiﬁcantly enhanced eNOS gene expression and enzyme
activity, and hence NO production, in in vitro assays (Räthel
et al., 2007; Appeldoorn et al., 2009). In contrast, Nicholson et al.
(Nicholson et al., 2010) reported that exposure of HUVECs to nano-
molar concentrations of resveratrol for 24 h increased the eNOS
mRNA level, although eNOS protein and NO production were not
affected. In the same cell line, Takahashi et al. demonstrated that
50 nM resveratrol did not alter the eNOS protein level or NO pro-
duction after 24 h of treatment, whereas daily treatment for 5 days
signiﬁcantly increased both eNOS protein and NO production with-
out producing any cytotoxic effects (Takahashi and Nakashima,
2011). Resveratrol also increased the synthesis of NO in ischemic
re-perfused rat tissue (Hattori et al., 2002) and preserved eNOS
phosphorylation in diabetic type 2 (db/db) mice (Zhang et al.,
2009).3. Impact of resveratrol on cerebrovascular diseases
Many studies have reported that the central nervous system is
targeted by resveratrol. This compound is in fact able to pass the
blood-brain barrier (Baur et al., 2006). Regarding its radical-scav-
enging activity, structural studies demonstrated that the hydroxyl
group at the 40 position of resveratrol is much easier to subject to
oxidation than other hydroxyl groups in the antioxidant reaction
(Caruso et al., 2004). Intraperitoneal administration of resveratrol
exerted neuroprotective effects, upregulating several endogenous
antioxidant enzymes, such as SOD and CAT, in the brain of healthy
rats (Mokni et al., 2007). Regarding the various isoforms of SOD,
SOD2 plays a more important role against oxidant-induced mito-
chondrial oxidative stress and cytotoxicity in neuronal cells (Vin-
cent et al., 2007). Fukui et al. demonstrated in HT22 neural cells
that the neuroprotective effect of resveratrol after glutamate-in-
duced cytotoxicity is largely independent of its direct antioxidant
activity; rather, this effect was mediated by induction of SOD2
expression via activation of the PI3K–AKT–GSK-3b–b-catenin sig-
naling pathway (Fukui et al., 2010). In rats, prolonged administra-
tion of resveratrol improved colchicine-induced cognitive
impairment, reduced malondialdehyde—an indicator of lipid per-
oxidation and nitrite levels—and restored depleted glutathione
(GSH), a ROS scavenger (Kumar et al., 2007).
It is interesting that resveratrol might be involved in the atten-
uation of neuroinﬂammatory responses because it is able to reduce
the concentration of 8-iso-prostaglandin F2a, an indicator of free-
radical generation in rat microglia (Candelario-Jalil et al., 2007). It
has also be shown that resveratrol inhibits COX1, but does not af-
fect the expression of COX2 (Davinelli et al., 2012). Since nuclear
factor-kb (NF-kb) signaling activation also plays an important role
in neurodegeneration, a link between Alzheimer’s Disease (AD) and
the neuroprotective activity of resveratrol is its ability to reduce, in
cultured rat astroglioma C6 cells, the expression of genes modu-
lated by NF-kb, such as inducible nitric oxide synthase (iNOS),
prostaglandin E2 (PGE2), as well as cathepsin and NO (Kim et al.,
2006). Resveratrol also attenuates LPS-stimulated NF-kb activation
in primary murine microglia and astrocytes, suggesting that the
inﬂammatory responses induced by LPS could be limited by resve-
ratrol (Lu et al., 2010).
In experimental models of stroke, Sinha et al. have shown a sig-
niﬁcant attenuation of malondialdhehyde and reduced GSH in the
rat middle-cerebral-artery occlusion model after 21 days of treat-
ment with 20 mg/kg BW trans-resveratrol (Sinha et al., 2002).
Moreover, resveratrol signiﬁcantly decreased oxidative stress
markers, including serum glycated albumin and urinary hydrox-
yguanosine, in stroke-prone spontaneously hypertensive rats(Mizutani et al., 2001). Also, studies performed on ischemia–reper-
fusion models have demonstrated that resveratrol inhibits peroxi-
some proliferator-activated receptors alpha (PPARa) (Inoue et al.,
2003) and reduces NF-kb p65 expression (Wang et al., 2003).
3.1. Resveratrol and SIRT1
Several studies have attributed resveratrol the capacity to stim-
ulate the activity of SIRT1 (Alcaín and Villalba, 2009). Conse-
quently, resveratrol administration appears to mimic caloric
restriction (Baur et al., 2006). A calorie-restricted diet has been
demonstrated to attenuate AD pathogenesis through an increase
in SIRT1 activity in a mouse model of AD (Saiko et al., 2008), and
also to reduce b-amyloid (Ab) deposition and Ab-associated neuro-
pathology in different animal models (Wang et al., 2005; Patel
et al., 2005; Gentile et al., 2009). Kim et al. showed in a transgenic
AD mouse model that resveratrol reduced neurodegeneration
through a decrease in the acetylation of known SIRT1 substrates,
for example peroxisome-proliferator-activated receptor gamma
coactivator alpha (PGC-1a) and p53 (Kim et al., 2006). Resvera-
trol-activated SIRT1 also reduced amyloid neuropathology in the
brains of Tg2576 mice and protected cells against Ab-induced
ROS production (Kelsey et al., 2010). Taking into account that res-
veratrol can be considered a neuroprotective compound in the con-
text of AD, it can be speculated that the ability to counteract Ab
toxicity is due to its antioxidant properties, but also due to SIRT1
activation.
The anti-amyloidogenic activity of resveratrol has been re-
ported in several studies: for example, Riviere et al. showed that
more than other stilbenes, resveratrol inhibits b-amyloid peptide
polymerization in vitro, even though its anti-amyloidogenic mech-
anism remained unknown (Rivière et al., 2007). As illustrated by
Marambaud and colleagues, resveratrol promotes clearance of
intracellular Ab by activating proteasomal degradation (Maram-
baud et al., 2005). Moreover, SIRT1 overexpression reduces Ab
pathology in APP-expressing neuronal cultures by delaying Ab syn-
thesis (Marambaud et al., 2005; Tang and Chua, 2008). Feng et al.
demonstrated that resveratrol disrupts Ab hydrogen binding, pre-
venting ﬁbril formation by destabilizing preformed ﬁbrils without
affecting oligomerization (Feng et al., 2009). Furthermore, studies
have shown that the protective effects of resveratrol on b-amy-
loid-induced toxicity are related to activation of PKC or AMPK
(Han et al., 2004; Karuppagounder et al., 2009).
3.2. Resveratrol and Nrf2
NRF2 is a key regulator of cellular antioxidant responses and ap-
pears to be a good candidate for neuroprotection in AD. In fact,
NRF2 regulates the expression of genes encoding antioxidant and
detoxifying proteins, such as glutathione S-transferase (GST), glu-
tathione synthetase (GSS), HO-1, and NAD(P)H-quinone oxidore-
ductase (Scapagnini et al., 2011). Under basal conditions, NRF2 is
sequestered in the cytoplasm by Kelch-like ECH-associating pro-
tein 1 (KEAP1), which facilitates its polyubiquitylation and protea-
some-mediated degradation. KEAP1 functions as a sensor of stress
signals. Exposure to oxidants disrupts the KEAP1–NRF2 complex,
stabilizing NRF2 and allowing it to accumulate in the nucleus.
NRF2 activates the transcription of its target genes via antioxidant
response elements (AREs) in their promoter regions, binding as a
heterodimer with members of the Maf and Jun families (Davinelli
et al., 2012). To date, only few studies have shown that the activa-
tion of NRF2 and of its antioxidant genes by resveratrol treatment
is sufﬁcient to protect against AD. However, Chen et al. reported
that resveratrol is able to increase the expression of HO-1 and
GSH, protecting PC12 cells from oxidative stress via activation of
the NRF2–ARE signaling pathway (Chen et al., 2005), which does
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was able to induce HO-1 in primary neuronal cultures, presumably
through the activation of NRF2 (Zhuang et al., 2003). The neuropro-
tective actions of HO-1 are attributable to the formation of biliver-
din and bilirubin during heme degradation, both of which can
serve as ROS scavengers (Otterbein and Choi, 2000; Stocker et al.,
2000). In conclusion, NRF2 is an attractive target for the discovery
of natural neuroprotective agents, such as resveratrol.4. Impact of resveratrol on diabetes
It has been proposed that oxidative stress caused especially by a
sedentary lifestyle and an unhealthy diet is an important risk factor
for the development of diabetes. Some studies have proposed res-
veratrol as a possible candidate for diabetes prevention.4.1. Resveratrol and NAD(P)H oxidase
Activation of NAD(P)H oxidase contributes to vascular oxida-
tive stress in experimental diabetes (Vecchione et al., 2006). In
particular, TNFa-mediated activation of NAD(P)H oxidase is
mainly responsible for the generation of the oxidative stress
encountered in the coronary microcirculation in type 2 diabetes
(Gao et al., 2007; Vecchione et al., 2007). The *O2 derived from
NAD(P)H oxidase can be dismutased to produce H2O2 (Papa and
Skulachev, 1997) or can be the cause of nitrative stress: in fact,
the interaction of *O2 with NO produces peroxynitrite, which
leads to protein tyrosine nitration generating nitrotyrosine, an
index of reactive nitrogen species; it also reduces NO bioavailabil-
ity, causing endothelial dysfunction (Shah and Channon, 2004).
Increased nitrotyrosine stress and peroxynitrite formation are
associated with diabetes development, as demonstrated in vari-
ous studies (Pacher et al., 2007; Frustaci et al., 2000; Pacher
and Szabo, 2006). For example, nitrotyrosine content was found
to be high in microvasculature endothelial cells of diabetic
patients (Ceriello et al., 2002). In the aorta of diabetic mice,
resveratrol was found to downregulate NAD(P)H oxidase expres-
sion, and thus contributed to a reduction in *O2 production
(Zhang et al., 2009). Aortic nitrotyrosine protein and H2O2 levels
also attenuate after treatment with resveratrol (Zhang et al.,
2009). In type 2 diabetic mice, Kitada et al. demonstrated that
resveratrol normalized Mn-SOD activity, through a reduction in
tyrosine-nitrate modiﬁcations and decreased urinary 8-hydroxy-
20-deoxyguanosine (8-OHdG), a marker of oxidative stress, and
O2 levels (Kitada et al., 2011).4.2. Resveratrol and nuclear factor-kB
Hyperglycemia—the hallmark of diabetes—can also induce
oxidative stress via several pathways that converge on NF-kb,
the activation of which in turn contributes to a further enhance-
ment of pro-inﬂammatory cytokines, oxidative stress, and apop-
tosis (Kern, 2007; Singh et al., 2011). In this context, resveratrol
was demonstrated to produce several anti-diabetic effects, such
as reduction of circulatory pro-inﬂammatory cytokines, inhibi-
tion of apoptosis, and concomitant enhancement of antioxidant
defenses (Lee et al., 2011; Palsamy and Subramanian, 2010;
Sharma et al., 2009, 2011; Zhang et al., 2010). It has been docu-
mented that short-term treatment of diabetic subjects with
resveratrol inhibited the activation of NF-kb at transcriptional
or post-transcriptional levels (Lee et al., 2009; Zhang et al.,
2010). Resveratrol may attenuate the inﬂammatory process
through a reduction of oxidative damage and NF-kb activity
(Kubota et al., 2009).4.3. Resveratrol and oxidative markers
Oxidation of glucose is another mechanism occurring in
diabetes (Maritim et al., 2003). Proteins such as hemoglobin and
antioxidant enzymes can be glycate in the presence of a high con-
centration of oxidated glucose. This leads to a reduction in detox-
iﬁcation of ROS, resulting in lipid-, protein-, and DNA-peroxidation,
and, ﬁnally, apoptosis (Rains and Jain, 2011). Glycated hemoglobin
(HbA1c) is a good marker for diagnosis and prognosis of complica-
tions in diabetes, such as retinopathy, nephropathy, and neuropa-
thy (Howlett and Ashwell, 2008). For example, it was shown that
reduction of HbA1c by only 1 unit (8–7%) can reduce the risk of ret-
inopathy by over 30% (Kowluru and Chan, 2007). Four months of
resveratrol supplementation was found to reduce HbA1c levels in
diabetic rats (Souﬁ et al., 2012).
Another good marker of oxidative and antioxidant homeostasis
is 8-isoprostane (8-iso-prostaglandin F2a), a product of the oxida-
tion of arachidonic acid present in phospholipids (Morrow et al.,
1995). It was reported that plasma levels of 8-isoprostane in-
creased with diabetes-induced lipid peroxidation and oxidative
stress (Ndisang et al., 2010; Salim et al., 2010). Moreover, retinal
8-isoprostane increased during hypoxia-induced retinopathy
(Kimura et al., 2007), and resveratrol reduced 8-isoprostane levels
in blood and retinal tissue of normal and diabetic rats, demonstrat-
ing that resveratrol has a strong antioxidant effect and attenuates
oxidative stress (Souﬁ et al., 2012).
In diabetes, the attenuation of oxidative stress reduces the level
of activated caspases and, thus, reduces apoptosis. In fact, resvera-
trol was found to modulate embryonic oxidative stress and apop-
tosis in diabetic pregnancy: in particular, it reduced oxidative
stress by restoring the level of reduced glutathione, total thiol, lipid
peroxidation, and 4-hydroxy-2-non-enal (HNE) in diabetic dams
(Singh et al., 2013).5. Toxicity of resveratrol
Many studies have investigated the toxic effect of resveratrol.
Most of the data available, both in human and in animal models,
suggest that resveratrol does not have a signiﬁcant toxic effect in
the wide range of concentrations tested (Ramprasath and Jones,
2010). For example, no toxic effects were found in rats after oral
administration of 20 mg/kg BW/day for 28 days, a dose higher than
that produced by one glass of red wine per day (Juan et al., 2002).
Moreover, no toxic effects were observed in rats given a supple-
mentation of 300 mg resveratrol/day for 4 weeks. In humans, Boo-
cock et al. found no toxicity after administration of a single dose of
up to 5 g resveratrol (Boocock et al., 2007). In addition, clinical, bio-
chemical, and hematological indices revealed no serious toxic ef-
fects in 44 healthy volunteers (10–12 per group) administered
resveratrol for 29 days at a daily dose of 0.5, 1.0, 2.5, or 5.0 g.
(Brown et al., 2010). However, adverse effects found in 28 partici-
pants were considered possibly due to resveratrol: common symp-
toms were gastrointestinal in nature, particularly diarrhea, nausea,
and abdominal pain, at a dose of 1 g. Typically, gastrointestinal
symptoms occurred 1 h after administration, and improved dur-
ing the course of the day. However, all the events were graded as
mild, according to the National Cancer Institute Common Termi-
nology Criteria for Adverse Events (CTCAE) (Ramprasath and Jones,
2010). Based on the these ﬁndings, the authors suggested that daily
doses of resveratrol for subsequent clinical evaluation should not
exceed 1 g. (Brown et al., 2010). Chow et al. reinforced those ﬁnd-
ings and demonstrated that 1 g resveratrol taken once daily for
4 week was generally well tolerated in healthy participants (Chow
et al., 2010): all the reported adverse events were CTC grade 1 or 2,
with many being mild and transient. The frequency of the side
Table 3
Summary of clinical trials on antioxidant effects of resveratrol. ;, downregualtion; ", upregulation.
References Sample population Resveratrol dose Duration Molecular-level effects
Ghanim et al. (2010) 20 healthy adults 40 mg 6 weeks ; ROS " TNF-a
; P47(phox)
; NFjB " IL-6
; JNK-1, " CRP
; PTP-1B " SOCS-3
Ghanim et al. (2011) 4 healthy men and 6 women 100 mg + 75 mg grapeskin 1 week ; ROS " Nrf-2
; TLR-4 " NQO-1
polyphenols ; CD14 " GST-P1
; IL-1b
; SOCS-3
Brasnyo et al. (2011) 19 diabetic men 5 mg twice daily 4 weeks, ; ROS " pAk
Timmers et al. (2011) 11 healthy obese men 150 mg twice daily 30 days ; glucose " AMPK
; insulin " SIRT1
; ROS " PGC1a
Bo et al. (2013) 50 healthy adult smokers 500 mg 30 days ; ROS
; CRP
;TG
Fig. 2. Representative scheme of the biological effects recruited by resveratrol and their involvement in cardiovascular, metabolic and cerebrovascular diseases.
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scribed by Brown et al. (Brown et al., 2010) and in shorter-term
studies involving fractionated daily doses (la Porte et al., 2010; Al-
meida et al., 2009; Nunes et al., 2009).
Finally, it is important to underline that resveratrol can exhibit
pro-oxidant activities in the presence of transition metal ions, such
as copper, leading to oxidative breakage of cellular DNA (de la Las-
tra and Villegas, 2007).
6. Clinical trials on the antioxidant effects of resveratrol
To date, only a small number of clinical trials on the antioxidant
effects of resveratrol have been reported. The most signiﬁcant
clinical trials are summarized in Table 3. Ghanim et al. (2010)
investigated the effects of resveratrol on different markers of
inﬂammation and oxidative stress in a randomized placebo-
controlled trial: the study was performed on 20 healthy adultsreceiving a 200 mg P. cuspidatum extract supplement containing
40 mg of resveratrol, for 6 weeks. Resveratrol did not alter fasting
plasma concentrations of cholesterol (total, LDL, and HDL), triglyc-
erides, or leptin compared with placebo. However, the treatment
reduced ROS levels, TNFa, and IL-6, and suppressed NF-kb in
mononuclear cells. Additionally, C-reactive protein (CRP)—another
important marker of inﬂammation—was signiﬁcantly reduced.
Ghanim et al. also conducted a separate crossover placebo-con-
trolled trial on 10 healthy humans fed with a high-fat, high-carbo-
hydrate meal (Ghanim et al., 2011). The 100 mg resveratrol
supplementation used signiﬁcantly increased NRF2-binding activ-
ity following the meal, and signiﬁcantly increased mRNA expres-
sion of important antioxidant enzymes, such as the NAD(P)H
dehydrogenase [quinone] 1 (NQO-1) and glutathione S-transferase
p1 (GST-p1). Resveratrol also attenuated the postprandial rise in
cluster of differentiation 14 (CD14), IL-1b mRNA, and toll-like
receptor 4 (TLR4) protein in mononuclear cells, while also
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dant and anti-inﬂammatory effects of resveratrol in response to
the high-fat, high-carbohydrate meal and a potential use in
reducing the risk of atherosclerosis and diabetes.
Interestingly, in a randomized double-blind placebo-controlled
crossover study, 5 mg trans-resveratrol supplementation given
twice daily for 4 weeks improved insulin sensitivity and lowered
blood glucose levels, delaying its peak (Brasnyo et al., 2011).
Among the mechanisms suggested to exert these beneﬁcial effects,
the authors indicated decreased oxidative stress and increased AKT
phosphorylation.
The metabolic effects of resveratrol have also been studied in
obese men (Timmers et al., 2011): supplementation with 75 mg
resveratrol for 30 days reduced sleeping- and resting-metabolic
rate in the absence of body weight changes; moreover, resveratrol
increased SIRT1 protein levels in muscle and reduced blood inﬂam-
mation markers.
Finally, Bo et al. evaluated the effects of resveratrol on healthy
smokers: they found that 500 mg resveratrol for 30 days signiﬁ-
cantly increased total antioxidant status values (Bo et al., 2013).
The authors suggested that resveratrol may reduce the risk of car-
diovascular diseases in smokers.
7. Conclusion and recommendations
In this review, we have focused our attention on the antioxidant
effects of resveratrol and on its molecular mechanisms. The neu-
tralization of free radicals prevents the activation of redox-sensi-
tive molecules involved in the modulation of biological process,
such as cell cycle and mitochondrial biogenesis, and of a wide
range of chronic diseases, including cardiovascular, neurological,
and metabolic disorders (Fig. 2). It is necessary to underline that
all antioxidant substances must be used at the proper dose, since
high concentrations may induce undesirable effects, such as
non-speciﬁc reactions with proteins, and decrease antioxidant
properties. Although a beneﬁcial ‘‘in vitro’’ antioxidant effect of
resveratrol on vessels from patients showing vascular dysfunction
is well deﬁned, further clinical trials need to determine resvera-
trol’s mechanism of action, its safety, and its toxicology. In the light
of existing data, it is clear that grapes—and wine—should be con-
sidered an integral component of fruit- and vegetable-enriched
diets that are recommended by health authorities and widely
accepted as beneﬁcial for human health and disease prevention.
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